Suhong Kim

Associate Director at TiCARos, INC at TiCARos

Presenter

Ticaros is a biotech that develops next-generation immuno-oncology drugs.

Recently, immuno-oncology therapy is gradually developing into a new fusion cell
therapy that combines antibody technology as well as immune cell therapy technology and gene therapy technology. In particular, the breakthrough therapeutic effect of CAR-T cell therapy and the potential for success
of TCR-T therapy are opening a new chapter in anticancer therapy.

Ticaros is developing unique CAR-T and cell therapy anticancer drugs based on the long-term immune cell research experience and technology of researchers at Seoul National University College of Medicine. Through this, we are focusing on the research and development of new gene cell therapies that can treat not only intractable blood cancers but also solid cancers.